FDA Declines Approval for AbbVie's TrenibotulinumtoxinE Citing Manufacturing Questions
AbbVie said the U.S. Food and Drug Administration declined to approve its experimental botulinum toxin treatment, trenibotulinumtoxinE, requesting additional manufacturing information while not raising safety or efficacy issues. The treatment, studied in more than 2,100 patients and shown to act quickly with a brief duration, faces a regulatory fol…